Asia
The purpose is to develop cell-based disease models to accelerate drug discovery and reduce development costs.
The disclosure comes the day before the WHO is expected to plan for the next phase of investigations into the origins of COVID-19.
Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.
If approved, Takeda said Maribavir would become the first and only treatment indicated for CMV infection in refractory patients.
Three companies on different continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.
Proxalutamide, a selective high-affinity silent antagonist of the androgen receptor, is being developed by Chinese biotech, Kintor Pharmaceutical Limited (9939.HK).
The help wanted signs are up across the biopharma industry. Companies are opening and expanding facilities, which is good news for job seekers.
Although a quiet week for COVID-19-related clinical trial announcements, there were plenty of others. Read on for more information.
PRESS RELEASES